Forbion Capital Partners

Forbion is a global venture capital firm focused on building and scaling innovative biotech companies and sustainable solutions to improve human and planetary health. They invest across multiple fund strategies, covering all stages of (bio-)pharmaceutical drug development. They leverage their biotech expertise beyond human health to address planetary health challenges through their BioEconomy fund strategy, which invests in companies developing sustainable solutions in food, agriculture, materials, and environmental technologies. Forbion aims to select impactful investments that will positively affect the health and well-being of people and the planet, as well as meet its financial return objectives. Their human health investment strategy includes Ventures, Growth, and Formation (spin-outs/company creation). The Ventures strategy builds and supports pre-clinical and early clinical companies. The Growth strategy focuses on providing capital for clinical stage drug development, primarily as private growth capital, and selectively as crossover and public investments. The Formation strategy runs a joint venture with BioGeneration Ventures (BGV) for early-stage investments, particularly in Benelux and Germany. Forbion's Planetary Health strategy focuses on innovative companies that leverage biotechnology to clean and feed the planet across four sectors: Food, Agriculture, Materials, and Environmental Technologies. The BioEconomy fund enables and grows companies in Series A+ rounds. Forbion seeks to identify companies with strong science, experienced teams, and clear paths to meaningful impact. They aim to shape category-defining therapeutics with global impact.

Biotech, Pharmaceuticals, Food, Agriculture, Materials, Environmental Technologies, Life Sciences

Core thematic spaces, technologies, and target market segments of interest.